GLUE Stock Analysis: Buy, Sell, or Hold?
GLUE - Monte Rosa Therapeutics, Inc. Common Stock
$16.52
-6.16 (-27.16%)
▼
5d:
-27.48%
30d:
-31.22%
90d:
-13.73%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
2d
Smart Money Accumulation
None View Scanner →
Strength: 7.5/10
Get Alerted When GLUE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GLUE is down 27.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GLUE is down 27.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GLUE is currently trading at $16.52, which is considered oversold relative to its 30-day fair value range of $20.95 to $24.46.
Technical Outlook: Technically, GLUE is showing support break momentum. Immediate support is located at $14.87, while resistance sits at $25.16. Short-term momentum is weak, with the stock down 27.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.83 (+110.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GLUE is showing support break momentum. Immediate support is located at $14.87, while resistance sits at $25.16. Short-term momentum is weak, with the stock down 27.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.83 (+110.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$20.95 -
$24.46
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding GLUE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-27.2%)
- BULLISH: Trading 110.9% below Wall St target ($34.83)
- WARNING: Recommendation downgraded due to -27.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$20.95 -
$24.46
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$14.87
Resistance Level
$25.16
Current Trend
Support Break
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.11
Wall Street Target
$34.83
(+110.9%)
Revenue Growth (YoY)
-95.0%
Share & Embed Analysis
Last updated: August 02, 2026 11:25 PM ET
Data refreshes hourly during market hours. Next update: 12:25 AM
Data refreshes hourly during market hours. Next update: 12:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLUE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Philip Nickson
SELL
5845 shares
2026-04-09
Edmund Dunn
SELL
139 shares
2026-03-04
Edmund Dunn
SELL
536 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
Advanced GLUE Option Strategies
Professional options setups generated by AI based on today's GLUE price and gamma walls.
